Trial Profile
Clinical study of Apapinib Combination with Crizotinib in Patients with Non-small cell lung cancer(NSCLC) who Developed Crizotinib Acpuired Resistance
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2017
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Nov 2017 New trial record